Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine in children aged 6-17 years: Final results of a phase 2, single-blind, randomised controlled trial (COV006).

Saved in:
Bibliographic Details
Title: Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine in children aged 6-17 years: Final results of a phase 2, single-blind, randomised controlled trial (COV006).
Authors: Li G; Oxford Vaccine Group, University of Oxford, UK. Electronic address: g.li@nhs.net., Marchevsky NG; Oxford Vaccine Group, University of Oxford, UK., Macaulay G; Oxford Vaccine Group, University of Oxford, UK., Aley P; Oxford Vaccine Group, University of Oxford, UK., Baughan H; Oxford Vaccine Group, University of Oxford, UK., Plested E; Oxford Vaccine Group, University of Oxford, UK., Bibi S; Oxford Vaccine Group, University of Oxford, UK., Cappuccini F; Oxford Vaccine Group, University of Oxford, UK., Faust SN; NIHR Southampton Clinical Research Facility and Biomedical Research Centre, University Hospital Southampton NHS Foundation Trust and Faculty of Medicine and Institute for Life Sciences, University of Southampton, Southampton, UK., Heath PT; Vaccine Institute, St George's, University of London and St George's University Hospitals NHS Trust, London, UK., Muller J; Oxford Vaccine Group, University of Oxford, UK., Robinson H; Oxford Vaccine Group, University of Oxford, UK., Roderick M; Bristol Royal Hospital for Children, University of Bristol, Bristol, UK., Snape M; Oxford Vaccine Group, University of Oxford, UK., Smith D; Oxford Vaccine Group, University of Oxford, UK., Song R; Oxford Vaccine Group, University of Oxford, UK., Liu X; Oxford Vaccine Group, University of Oxford, UK., Lambe T; Oxford Vaccine Group, University of Oxford, UK; Chinese Academy of Medical Sciences Oxford Institute, Oxford, UK., Pollard AJ; Oxford Vaccine Group, University of Oxford, UK; Oxford NIHR Biomedical Research Centre, Oxford, UK, Oxford, UK.
Corporate Authors: COV006 trial team
Source: Vaccine [Vaccine] 2025 Aug 30; Vol. 62, pp. 127597. Date of Electronic Publication: 2025 Aug 25.
Publication Type: Journal Article; Randomized Controlled Trial; Clinical Trial, Phase II; Multicenter Study
Journal Info: Publisher: Elsevier Science Country of Publication: Netherlands NLM ID: 8406899 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1873-2518 (Electronic) Linking ISSN: 0264410X NLM ISO Abbreviation: Vaccine Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1873-2518
DOI:10.1016/j.vaccine.2025.127597